Euphylline (Tablets, Solution) Instructions for Use

Instructions
Dosage forms

ATC Code

R03DA05 (Aminophylline)

Active Substance

Aminophylline (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Bronchodilator drug – phosphodiesterase inhibitor

Pharmacotherapeutic Group

Drugs for the treatment of obstructive airway diseases; other systemic drugs for the treatment of obstructive airway diseases; xanthines

Pharmacological Action

Bronchodilator agent, phosphodiesterase inhibitor. It is the ethylenediamine salt of theophylline (which facilitates solubility and increases absorption). It has a bronchodilatory effect, apparently due to a direct relaxing effect on the smooth muscles of the airways and pulmonary blood vessels.

This action is believed to be caused by selective suppression of the activity of specific phosphodiesterases, leading to an increase in intracellular cAMP concentration. Results from in vitro experimental studies show that type III and IV isoenzymes likely play the main role. Suppression of the activity of these isoenzymes may also cause some side effects of aminophylline (theophylline), including vomiting, arterial hypotension, and tachycardia.

It blocks adenosine (purine) receptors, which may be one of the factors of its action on the bronchi.

It reduces airway hyperreactivity associated with the late phase of the reaction caused by inhalation of allergens, through an unknown mechanism that is not related to phosphodiesterase inhibition or blockade of adenosine action. There are reports that Aminophylline increases the number and activity of T-suppressors in peripheral blood.

It increases mucociliary clearance, stimulates diaphragm contraction, improves the function of respiratory and intercostal muscles, stimulates the respiratory center, increases its sensitivity to carbon dioxide, and improves alveolar ventilation, which ultimately leads to a reduction in the severity and frequency of apnea episodes.

By normalizing respiratory function, it promotes oxygen saturation of the blood and reduces the concentration of carbon dioxide. It enhances lung ventilation under conditions of hypokalemia.

It has a stimulating effect on heart activity, increases strength and heart rate, increases coronary blood flow, and increases myocardial oxygen demand. It reduces the tone of blood vessels (mainly vessels of the brain, skin, and kidneys). It has a peripheral venodilating effect, reduces pulmonary vascular resistance, and lowers pressure in the pulmonary circulation.

It increases renal blood flow and has a moderate diuretic effect. It dilates the extrahepatic bile ducts. It stabilizes mast cell membranes and inhibits the release of allergic reaction mediators. It inhibits platelet aggregation (suppresses platelet-activating factor and PgE_2α), increases the resistance of erythrocytes to deformation (improves the rheological properties of blood), reduces thrombus formation, and normalizes microcirculation.

It has a tocolytic effect and increases the acidity of gastric juice. In high doses, it has an epileptogenic effect.

Pharmacokinetics

Aminophylline is metabolized in the body at physiological pH values with the release of free theophylline. Bronchodilating properties are manifested at theophylline plasma concentrations of 10-20 µg/ml. A concentration above 20 mg/ml is toxic. The excitatory effect on the respiratory center is realized at a lower concentration – 5-10 µg/ml.

The binding of theophylline to plasma proteins is approximately 40%; in newborns, as well as in adults with diseases, binding is reduced. Binding to plasma proteins in adults is about 60%, in newborns – 36%, in patients with liver cirrhosis – 36%. It penetrates the placental barrier (the concentration in the fetal serum is somewhat higher than in the maternal serum). It is excreted in breast milk.

Theophylline is metabolized in the liver with the participation of several cytochrome P450 isoenzymes, the most important of which is CYP1A2. During metabolism, 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine are formed. These metabolites are excreted in the urine. In unchanged form, 10% is excreted in adults. In newborns, a significant portion is excreted as caffeine (due to the immaturity of its further metabolic pathways), and 50% is excreted unchanged.

Significant individual differences in the rate of hepatic metabolism of theophylline are the cause of pronounced variability in clearance values, plasma concentration, and half-life. Hepatic metabolism is influenced by factors such as age, tobacco smoking habit, diet, diseases, and concurrent drug therapy.

The T_1/2 of theophylline in non-smoking patients with bronchial asthma with practically no pathological changes in other organs and systems is 6-12 hours, in smokers – 4-5 hours, in children – 1-5 hours, in newborns and premature infants – 10-45 hours.

The T_1/2 of theophylline increases in the elderly and in patients with heart failure or liver diseases.

Clearance decreases in heart failure, impaired liver function, chronic alcoholism, pulmonary edema, and COPD.

Ethylenediamine does not affect the pharmacokinetics of theophylline.

Indications

For parenteral use: status asthmaticus (adjunctive therapy), neonatal apnea, cerebrovascular accident of the ischemic type (as part of combination therapy), left ventricular failure with bronchospasm and Cheyne-Stokes respiration, renal edema syndrome (as part of complex therapy); acute and chronic heart failure (as part of combination therapy).

For oral administration: bronchial obstruction syndrome of various origins (including bronchial asthma, COPD, including pulmonary emphysema, chronic obstructive bronchitis), hypertension in the pulmonary circulation, cor pulmonale, nocturnal apnea; acute and chronic heart failure (as part of combination therapy).

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
G47.3	Sleep apnea (disorders of the respiratory center)
I27.0	Primary pulmonary hypertension
I27.2	Other secondary pulmonary hypertension
I27.8	Other specified forms of pulmonary heart failure
I27.9	Pulmonary heart failure, unspecified (including cor pulmonale (chronic) NOS)
I50.0	Congestive heart failure
I50.1	Left ventricular failure
I63	Cerebral infarction
J43	Emphysema
J44	Other chronic obstructive pulmonary disease
J45	Asthma
J46	Status asthmaticus
N04	Nephrotic syndrome
P28.3	Primary sleep apnea of newborn
P28.4	Other apneas of newborn

ICD-11 code	Indication
7A40.1	Primary central sleep apnea of infancy
7A4Z	Sleep-related breathing disorders, unspecified
8B11	Cerebral ischemic stroke
BB01.0	Pulmonary arterial hypertension
BB01.1	Pulmonary hypertension due to left heart disease
BB01.2	Pulmonary hypertension due to lung diseases or hypoxia
BB01.4	Pulmonary hypertension with multifactorial mechanisms
BB01.Z	Pulmonary hypertension, unspecified
BB0Z	Diseases of pulmonary circulation and right heart, unspecified
BD10	Congestive heart failure
BD11.Z	Left ventricular failure, unspecified
CA21.Z	Emphysema, unspecified
CA22.Z	Chronic obstructive pulmonary disease, unspecified
CA23	Asthma
CA23.01	Allergic asthma with status asthmaticus
CA23.11	Non-allergic asthma with status asthmaticus
CA23.31	Unspecified asthma with status asthmaticus
GB41	Nephrotic syndrome
KB2Z	Respiratory disorders specific to the perinatal or neonatal period, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Solution

Individual, depending on the indications, age, clinical situation, route and scheme of administration, nicotine dependence.

Tablets

Orally, adults should be prescribed 150 mg per dose 1-3 times a day after meals. Children should be prescribed orally at the rate of 7-10 mg/kg per day in 4 divided doses. The duration of the course of treatment is from several days to several months, depending on the course of the disease and the tolerability of the drug.

Maximum doses of Euphylline for adults orally: single – 0.5 g, daily – 1.5 g. Maximum doses for children orally: single – 7 mg/kg, daily – 15 mg/kg.

Adverse Reactions

From the nervous system dizziness, sleep disturbances, anxiety, tremor, convulsions.

From the cardiovascular system palpitations, cardiac rhythm disturbances; with rapid IV administration – appearance of pain in the heart area, decreased blood pressure, tachycardia (including in the fetus when taken in the III trimester of pregnancy), arrhythmias, decreased blood pressure, cardialgia, increased frequency of angina attacks.

From the digestive system nausea, vomiting, gastroesophageal reflux, heartburn, exacerbation of peptic ulcer, diarrhea; with prolonged oral administration – anorexia.

From the urinary system albuminuria, hematuria.

Allergic reactions skin rash, itching, fever.

From metabolism rarely – hypoglycemia.

Local reactions induration, hyperemia, pain at the injection site; with rectal application, irritation of the rectal mucosa, proctitis.

Other chest pain, tachypnea, feeling of flushing to the face, albuminuria, hematuria, hypoglycemia, increased diuresis, increased sweating.

Contraindications

Severe arterial hyper- or hypotension, tachyarrhythmias, gastric and duodenal ulcer in the acute phase, hyperacid gastritis, severe impairment of liver and/or kidney function, epilepsy, hemorrhagic stroke, retinal hemorrhage, simultaneous use with ephedrine in children, children’s age (up to 3 years, for prolonged oral forms – up to 12 years), hypersensitivity to aminophylline and theophylline.

Use in Pregnancy and Lactation

Theophylline crosses the placental barrier. The use of aminophylline during pregnancy can lead to the creation of potentially dangerous concentrations of theophylline and caffeine in the plasma of the newborn. Newborns whose mothers received Aminophylline during pregnancy (especially in the III trimester) require medical supervision to monitor possible symptoms of theophylline intoxication.

Theophylline is excreted in breast milk. When using aminophylline in a nursing mother during lactation, irritability may appear in the child.

Thus, the use of aminophylline during pregnancy and lactation (breastfeeding) is possible in cases where the intended therapeutic benefit for the mother outweighs the potential risk to the fetus or child.

Use in Hepatic Impairment

Contraindicated in severe liver dysfunction.

Use with caution in hepatic insufficiency.

Use in Renal Impairment

Contraindicated in severe renal dysfunction.

Use with caution in renal insufficiency.

Pediatric Use

Contraindication: children’s age (up to 3 years, for prolonged oral forms – up to 12 years). Do not use rectally in children.

Geriatric Use

With caution: elderly patients (dose reduction may be required).

Special Precautions

Use with caution in severe coronary insufficiency (acute phase of myocardial infarction, angina pectoris), widespread atherosclerosis, hypertrophic obstructive cardiomyopathy, frequent ventricular extrasystole, increased convulsive readiness, in hepatic and/or renal insufficiency, gastric and duodenal ulcer (in history), with recently occurred gastrointestinal bleeding, uncontrolled hypothyroidism (possibility of accumulation) or thyrotoxicosis, with prolonged hyperthermia, gastroesophageal reflux, prostatic hyperplasia, in elderly patients, in children (especially orally).

Correction of the aminophylline dosing regimen may be required in heart failure, impaired liver function, chronic alcoholism, fever, acute respiratory infections.

In elderly patients, a dose reduction may be required.

When switching from one dosage form of aminophylline to another, clinical monitoring and control of theophylline plasma concentration are necessary.

Aminophylline should not be used simultaneously with other xanthine derivatives. During treatment, the consumption of food products containing xanthine derivatives (strong coffee, tea) should be avoided.

Use with caution simultaneously with anticoagulants, with other derivatives of theophylline or purine.

Simultaneous use with beta-blockers should be avoided.

Aminophylline should not be used simultaneously with glucose solution.

Do not use rectally in children.

Drug Interactions

With simultaneous use with sympathomimetics, mutual enhancement of action occurs; with beta-blockers and lithium preparations – the action is mutually reduced. The intensity of the action of aminophylline may decrease (due to an increase in its clearance) with simultaneous use with phenobarbital, rifampicin, isoniazid, carbamazepine, sulfinpyrazone, phenytoin, as well as in smokers.

The intensity of the action of aminophylline may increase (due to a decrease in its clearance) with simultaneous use with antibiotics from the macrolide group, lincomycin, with quinolones, allopurinol, beta-blockers, cimetidine, disulfiram, fluvoxamine, oral hormonal contraceptives, isoprenaline, viloxazine, and during influenza vaccination.

Xanthine derivatives may potentiate hypokalemia caused by the action of β₂-adrenergic receptor stimulants, corticosteroids, and diuretics.

Antidiarrheal drugs and enterosorbents reduce the absorption of aminophylline.

Pharmaceutically incompatible with acid solutions.

Storage Conditions

Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Euphylline [Mapichem AG (Switzerland)]
Solution for intravenous administration 120 mg/5 ml: amp. 10, 100, 200, or 300 pcs.

Marketing Authorization Holder

Mapichem AG (Switzerland)

Manufactured By

Shandong Shenglu Pharmaceutical, Co.Ltd. (China)

Dosage Form

Euphylline

Solution for intravenous administration 120 mg/5 ml: amp. 10, 100, 200, or 300 pcs.

Dosage Form, Packaging, and Composition

Solution for IV administration	1 ml	1 amp.
Aminophylline	24 mg	120 mg

5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) – contour plastic packaging (1) – cardboard packs.
5 ml – ampoules (10) – contour plastic packaging (10) – cardboard packs.
5 ml – ampoules (10) – contour plastic packaging (20) – cardboard packs.
5 ml – ampoules (10) – contour plastic packaging (30) – cardboard packs.

Euphylline [Mapichem AG (Switzerland)]
Solution for intravenous administration 240 mg/10 ml: amp. 10, 100, 200, or 300 pcs.

Marketing Authorization Holder

Mapichem AG (Switzerland)

Manufactured By

Shandong Shenglu Pharmaceutical, Co.Ltd. (China)

Dosage Form

Euphylline

Solution for intravenous administration 240 mg/10 ml: amp. 10, 100, 200, or 300 pcs.

Dosage Form, Packaging, and Composition

Solution for IV administration	1 ml	1 amp.
Aminophylline	24 mg	240 mg

10 ml – ampoules (10) – cardboard packs.
10 ml – ampoules (10) – contour plastic packaging (1) – cardboard packs.
10 ml – ampoules (10) – contour plastic packaging (10) – cardboard packs.
10 ml – ampoules (10) – contour plastic packaging (20) – cardboard packs.
10 ml – ampoules (10) – contour plastic packaging (30) – cardboard packs.

Euphylline [Armavir Biopharmaceutical Plant, FSE (Russia)]
Solution for intravenous administration 120 mg/5 mL: 5 and 10 amp.

Marketing Authorization Holder

Armavir Biopharmaceutical Plant, FSE (Russia)

Dosage Form

Euphylline

Solution for intravenous administration 120 mg/5 mL: 5 and 10 amp.

Dosage Form, Packaging, and Composition

Solution for IV administration	1 ml	1 amp.
Aminophylline	24 mg	120 mg

5 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Euphylline [Armavir Biopharmaceutical Plant, FSE (Russia)]
Solution for intravenous administration 240 mg/10 mL: 5 and 10 amp.

Marketing Authorization Holder

Armavir Biopharmaceutical Plant, FSE (Russia)

Dosage Form

Euphylline

Solution for intravenous administration 240 mg/10 mL: 5 and 10 amp.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Aminophylline	24 mg	240 mg

10 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
10 ml – ampoules (10) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Euphylline [Atoll LLC (Russia)]
Tablets 150 mg: 10, 20, 30, 40, 50, 60, or 100 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Euphylline

Tablets 150 mg: 10, 20, 30, 40, 50, 60, or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets round, flat-cylindrical, with a score and a bevel, white or white with a yellowish tint.

	1 tab.
Aminophylline	150 mg

Excipients: corn starch – 47.7 mg, potato starch – 0.03 mg, magnesium stearate – 2 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
20 pcs. – contour cell packs (1) – cardboard packs.
20 pcs. – contour cell packs (2) – cardboard packs.
20 pcs. – contour cell packs (3) – cardboard packs.
20 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – contour cell packs (5) – cardboard packs.
20 pcs. – contour cell packs (6) – cardboard packs.
20 pcs. – contour cell packs (10) – cardboard packs.
30 pcs. – contour cell packs (1) – cardboard packs.
30 pcs. – contour cell packs (2) – cardboard packs.
30 pcs. – contour cell packs (3) – cardboard packs.
30 pcs. – contour cell packs (4) – cardboard packs.
30 pcs. – contour cell packs (5) – cardboard packs.
30 pcs. – contour cell packs (6) – cardboard packs.
30 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.

Euphylline [Atoll LLC (Russia)]
Solution for intravenous administration 24 mg/1 ml: 5 ml or 10 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Euphylline

Solution for intravenous administration 24 mg/1 ml: 5 ml or 10 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration transparent, colorless or slightly colored.

	1 ml
Aminophylline (calculated as the anhydrous substance)	24 mg

Excipients: water for injections – up to 1 ml.

5 ml – glass ampoules (5) – contour cell packs (1) – cardboard packs.
5 ml – glass ampoules (5) – contour cell packs (2) – cardboard packs.
10 ml – glass ampoules (5) – contour cell packs (1) – cardboard packs.
10 ml – glass ampoules (5) – contour cell packs (2) – cardboard packs.
5 ml – glass ampoules (5) – cardboard trays (1) – cardboard packs.
5 ml – glass ampoules (5) – cardboard trays (2) – cardboard packs.
10 ml – glass ampoules (5) – cardboard trays (1) – cardboard packs.
10 ml – glass ampoules (5) – cardboard trays (2) – cardboard packs.

Euphylline [Biosintez, PJSC (Russia)]
Tablets 150 mg: 10, 20, or 30 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Euphylline

Tablets 150 mg: 10, 20, or 30 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical, with a bevel.

	1 tab.
Aminophylline	150 mg

Tablets	1 tab.
Aminophylline	150 mg

Euphylline [Grotex, LLC (Russia)]
Solution for intravenous administration 24 mg/ml: 5 ml or 10 ml amp. 5 or 10 pcs.

Marketing Authorization Holder

Grotex, LLC (Russia)

Dosage Form

Euphylline

Solution for intravenous administration 24 mg/ml: 5 ml or 10 ml amp. 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration in the form of a colorless or slightly colored transparent liquid.

	1 ml
Aminophylline	24 mg

Solution for intravenous administration transparent, colorless or slightly colored.

	1 ml	1 amp.
Aminophylline	24 mg	240 mg

Excipients: water for injections.

10 ml – ampoules (10) – cardboard boxes.

Euphylline [Novosibkhimpharm, JSC (Russia)]
Solution for intravenous administration 120 mg/5 mL: 5, 10, or 20 amp.

Marketing Authorization Holder

Novosibkhimpharm, JSC (Russia)

Dosage Form

Euphylline

Solution for intravenous administration 120 mg/5 mL: 5, 10, or 20 amp.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Aminophylline	24 mg	120 mg,
Including theophylline	19.2 mg	96 mg
Ethylenediamine	4.8 mg	24 mg

5 ml – ampoules (10) in a set with an ampoule knife or scarifier, if necessary for this type of ampoules – cardboard boxes.
5 ml – ampoules (10) – plastic contour packs (1) – cardboard packs.
5 ml – ampoules (10) – plastic contour packs (2) – cardboard packs.
5 ml – ampoules (5) – plastic contour packs (1) – cardboard packs.
5 ml – ampoules (5) – plastic contour packs (2) – cardboard packs.

Euphylline [Novosibkhimpharm, JSC (Russia)]
Solution for intravenous administration 240 mg/10 ml: amp. 5, 10, or 20 pcs.

Marketing Authorization Holder

Novosibkhimpharm, JSC (Russia)

Dosage Form

Euphylline

Solution for intravenous administration 240 mg/10 ml: amp. 5, 10, or 20 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml	1 amp.
Aminophylline	24 mg	240 mg,
Including theophylline	19.2 mg	192 mg
Ethylenediamine	4.8 mg	48 mg

10 ml – ampoules (10) in a set with an ampoule knife or scarifier, if necessary for this type of ampoules – cardboard boxes.
10 ml – ampoules (10) – contour cell packs (1) – cardboard packs.
10 ml – ampoules (10) – contour cell packs (2) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
10 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Euphylline [Microgen NPO, JSC (Russia)]
Solution for intravenous administration 24 mg/1 ml: amp. 5 ml 10 pcs.
Solution for intravenous administration 24 mg/1 ml: amp. 10 ml 10 pcs.

Marketing Authorization Holder

Microgen NPO, JSC (Russia)

Dosage Forms

	Euphylline	Solution for intravenous administration 24 mg/1 ml: amp. 5 ml 10 pcs.
		Solution for intravenous administration 24 mg/1 ml: amp. 10 ml 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration clear, colorless or slightly yellowish.

	1 ml	1 amp.
Aminophylline	24 mg	120 mg

Excipients : water for injections – up to 1 ml.

5 ml – ampoules (10) – cardboard packs.
5 ml – ampoules (10) with a scarifier – cardboard packs.
5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Solution for intravenous administration clear, colorless or slightly yellowish.

	1 ml	1 amp.
Aminophylline	24 mg	240 mg

Tablets white or white with a yellowish tint, round, flat-cylindrical in shape, with a bevel.

	1 tab.
Aminophylline	150 mg

Excipients : potato starch – 48 mg, calcium stearate – 2 mg.

10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.
100 pcs. – polymer jars (1) – cardboard packs.
10 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
20 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
30 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
40 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
50 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
60 pcs. – polyethylene terephthalate jars (1) – cardboard packs.
100 pcs. – polyethylene terephthalate jars (1) – cardboard packs.

Euphylline [Pharmasintez, JSC (Russia)]
Tablets 150 mg: 10, 20, 30, 50 or 100 pcs.

Marketing Authorization Holder

Pharmasintez, JSC (Russia)

Dosage Form

Euphylline

Tablets 150 mg: 10, 20, 30, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Aminophylline	150 mg

Euphylline [Pharmstandard-Lexredstva OJSC (Russia)]
Tablets 150 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, or 100 pcs.

Marketing Authorization Holder

Pharmstandard-Lexredstva OJSC (Russia)

Dosage Form

Euphylline

Tablets 150 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75, or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white or white with a yellowish tint, round, flat-cylindrical.

	1 tab.
Aminophylline (euphylline)	150 mg

Excipients : potato starch – 48.5 mg, calcium stearate – 1.5 mg.

Euphylline-Darnitsa [Darnitsa Pharmaceutical Firm, PJSC (Ukraine)]
Solution for intravenous administration 24 mg/1 ml: 5 ml amp. 5 and 10 pcs.

Marketing Authorization Holder

Darnitsa Pharmaceutical Firm, PJSC (Ukraine)

Dosage Form

Euphylline-Darnitsa

Solution for intravenous administration 24 mg/1 ml: 5 ml amp. 5 and 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml
Aminophylline	24 mg

5 ml – ampoules (5) – contour cell packs (1) – cardboard packs.
5 ml – ampoules (5) – contour cell packs (2) – cardboard packs.

Euphylline-Darnitsa [Darnitsa Pharmaceutical Firm, PJSC (Ukraine)]
Solution for intravenous administration 240 mg/1 ml: amp. 10 pcs.

Marketing Authorization Holder

Darnitsa Pharmaceutical Firm, PJSC (Ukraine)

Dosage Form

Euphylline-Darnitsa

Solution for intravenous administration 240 mg/1 ml: amp. 10 pcs.

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml
Aminophylline	240 mg

1 ml – ampoules (10) – contour cell packs (1) – cardboard packs.
10 ml – ampoules (1) – cardboard packs.

Euphylline-Eskom [Mir Chemical and Pharmaceutical Concern, LLC (Russia)]
Solution for intravenous administration 24 mg/1 ml: amp. 5 ml or 10 ml

Marketing Authorization Holder

Mir Chemical and Pharmaceutical Concern, LLC (Russia)

Manufactured By

NPC Eskom, PJSC (Russia)

Dosage Form

Euphylline-Eskom

Solution for intravenous administration 24 mg/1 ml: amp. 5 ml or 10 ml

Dosage Form, Packaging, and Composition

Solution for intravenous administration	1 ml
Aminophylline	24 mg

5 ml – glass ampoules (5) – plastic contour packs (1) – cardboard packs.
5 ml – glass ampoules (5) – plastic contour packs (2) – cardboard packs.
5 ml – glass ampoules (10) – plastic contour packs (1) – cardboard packs.
5 ml – glass ampoules (10) – plastic contour packs (2) – cardboard packs.
10 ml – glass ampoules (5) – plastic contour packs (1) – cardboard packs.
10 ml – glass ampoules (5) – plastic contour packs (2) – cardboard packs.
10 ml – glass ampoules (10) – plastic contour packs (1) – cardboard packs.
10 ml – glass ampoules (10) – plastic contour packs (2) – cardboard packs.

Euphylline-UBF [Uralbiopharm, JSC (Russia)]
Tablets 150 mg: 10, 20, 25, 30, 40, or 50 pcs.

Marketing Authorization Holder

Uralbiopharm, JSC (Russia)

Dosage Form

Euphylline-UBF

Tablets 150 mg: 10, 20, 25, 30, 40, or 50 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Aminophylline	150 mg

10 pcs. – polymer jars (1) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
25 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
50 pcs. – polymer jars (1) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
60 pcs. – polymer jars (1) – cardboard packs.

Medixlife (Author)

View all posts Profile link